Yu Abe

414 total citations
27 papers, 326 citations indexed

About

Yu Abe is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Yu Abe has authored 27 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 13 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Yu Abe's work include Multiple Myeloma Research and Treatments (16 papers), Cancer Treatment and Pharmacology (5 papers) and Peptidase Inhibition and Analysis (5 papers). Yu Abe is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Cancer Treatment and Pharmacology (5 papers) and Peptidase Inhibition and Analysis (5 papers). Yu Abe collaborates with scholars based in Japan, Australia and United States. Yu Abe's co-authors include Kenshi Suzuki, Yasunori Nakagawa, Kiyoshi Yokokawa, Andrew J. Nicol, Mie Nieda, Shigenori Goto, Tadao Ishida, Naoya Kojima, Nobuhiro Tsukada and T. Kajiwara and has published in prestigious journals such as Blood, The Journal of Biochemistry and Glycobiology.

In The Last Decade

Yu Abe

25 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yu Abe Japan 9 186 169 102 99 33 27 326
Bjarne Bogen Norway 13 329 1.8× 205 1.2× 143 1.4× 143 1.4× 75 2.3× 21 493
Hui Qin China 7 171 0.9× 169 1.0× 125 1.2× 71 0.7× 53 1.6× 14 325
Niken M. Mahaweni Netherlands 8 234 1.3× 125 0.7× 135 1.3× 43 0.4× 24 0.7× 9 377
Franziska Brauneck Germany 11 244 1.3× 192 1.1× 72 0.7× 37 0.4× 12 0.4× 21 387
Soroosh Radfar United States 7 229 1.2× 130 0.8× 113 1.1× 27 0.3× 12 0.4× 10 363
Aldo Gasparollo Italy 7 236 1.3× 90 0.5× 133 1.3× 48 0.5× 47 1.4× 9 343
Tina Nuebling Germany 9 270 1.5× 247 1.5× 132 1.3× 106 1.1× 22 0.7× 13 455
Philip McCoy United States 5 260 1.4× 194 1.1× 93 0.9× 82 0.8× 26 0.8× 11 383
Johannes M. Waldschmidt Germany 9 45 0.2× 158 0.9× 149 1.5× 207 2.1× 28 0.8× 53 310
Esten N. Vandsemb Norway 9 174 0.9× 181 1.1× 209 2.0× 46 0.5× 15 0.5× 15 408

Countries citing papers authored by Yu Abe

Since Specialization
Citations

This map shows the geographic impact of Yu Abe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Abe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Abe more than expected).

Fields of papers citing papers by Yu Abe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Abe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Abe. The network helps show where Yu Abe may publish in the future.

Co-authorship network of co-authors of Yu Abe

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Abe. A scholar is included among the top collaborators of Yu Abe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Abe. Yu Abe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kikuchi, Taku, Nobuhiro Tsukada, Yuki Oda, et al.. (2024). Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma. International Journal of Hematology. 120(1). 91–95. 1 indexed citations
2.
Kikuchi, Taku, Nobuhiro Tsukada, Yuki Oda, et al.. (2023). Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment. Annals of Hematology. 102(6). 1477–1483. 10 indexed citations
3.
Abe, Yu, Makoto Sasaki, Naoki Takezako, et al.. (2023). Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma. Annals of Hematology. 102(9). 2493–2504. 1 indexed citations
4.
Kikuchi, Taku, Nobuhiro Tsukada, Yuki Oda, et al.. (2023). Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies. Annals of Hematology. 102(12). 3489–3497. 2 indexed citations
5.
6.
Okazuka, Kiyoshi, Tadao Ishida, Jun Sakamoto, et al.. (2021). Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry. Annals of Hematology. 100(12). 2989–2995. 2 indexed citations
7.
Okazuka, Kiyoshi, Yumiko Yoshiki, Yu Abe, et al.. (2019). Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis. International Journal of Hematology. 110(4). 431–437. 3 indexed citations
8.
Okazuka, Kiyoshi, Tadao Ishida, Yumiko Yoshiki, et al.. (2019). The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma. European Journal Of Haematology. 104(2). 110–115. 9 indexed citations
9.
Abe, Yu & Tadao Ishida. (2019). Immunomodulatory drugs in the treatment of multiple myeloma. Japanese Journal of Clinical Oncology. 49(8). 695–702. 20 indexed citations
10.
Ishida, Tadao, Masahiro Ikeda, Sumito Shingaki, et al.. (2018). [IgE-κ type multiple myeloma achieving complete response with novel agents].. PubMed. 58(11). 2232–2237. 1 indexed citations
11.
Iyoda, Tomonori, Satoru Yamasaki, Michihiro Hidaka, et al.. (2017). Amelioration of NK cell function driven by Vα24 + invariant NKT cell activation in multiple myeloma. Clinical Immunology. 187. 76–84. 14 indexed citations
12.
Iida, Shinsuke, Kenshi Suzuki, Shigeru Kusumoto, et al.. (2017). Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study. International Journal of Hematology. 106(4). 541–551. 13 indexed citations
13.
Suzuki, Kenshi, Michinori Ogura, Yu Abe, et al.. (2015). Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. International Journal of Hematology. 101(3). 286–294. 24 indexed citations
14.
Tsukada, Nobuhiro, Masahiro Ikeda, Sumito Shingaki, et al.. (2015). High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases. International Journal of Hematology. 103(3). 299–305. 5 indexed citations
15.
Suzuki, Kenshi, et al.. (2015). Difference of Treatment Outcomes in AL Amyloidosis and Multiple Myeloma with / without Translocation (11;14). Blood. 126(23). 4224–4224. 1 indexed citations
16.
Abe, Yu, et al.. (2012). Chronic Neutropenia with Variegated Infectious Symptoms.. Nihon Naika Gakkai Zasshi. 101(1). 150–153. 1 indexed citations
17.
Abe, Yu, Mie Nieda, Yasunori Nakagawa, et al.. (2009). Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma. Experimental Hematology. 37(8). 956–968. 151 indexed citations
18.
Shiraishi, Junichi, Yasunori Nakagawa, Morito Kurata, et al.. (2008). Follicular lymphoma with marked infiltration of eosinophils. Pathology International. 58(11). 701–705. 6 indexed citations
19.
20.
Abe, Yu, Yasuhiro Kuroda, Noritaka Kuboki, et al.. (2008). Contribution of Complement Component C3 and Complement Receptor Type 3 to Carbohydrate-dependent Uptake of Oligomannose-coated Liposomes by Peritoneal Macrophages. The Journal of Biochemistry. 144(5). 563–570. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bjarne Bogen Breakdown of academic impact, for papers by Hui Qin Breakdown of academic impact, for papers by Niken M. Mahaweni Breakdown of academic impact, for papers by Franziska Brauneck Breakdown of academic impact, for papers by Soroosh Radfar Breakdown of academic impact, for papers by Aldo Gasparollo Breakdown of academic impact, for papers by Tina Nuebling Breakdown of academic impact, for papers by Philip McCoy Breakdown of academic impact, for papers by Johannes M. Waldschmidt Breakdown of academic impact, for papers by Esten N. Vandsemb
Rankless by CCL
2026